For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
DelveInsight's Systemic Lupus Erythematosus (SLE) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of SLE in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Systemic Lupus Erythematosus (SLE) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2016-2027
Systemic Lupus Erythematosus- Disease Understanding and Treatment Algorithm
The DelveInsight Systemic Lupus Erythematosus market report gives the thorough understanding of the Systemic Lupus Erythematosus by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Systemic Lupus Erythematosus in the US, Europe, and Japan.
Systemic Lupus Erythematosus Epidemiology
The Systemic Lupus Erythematosus (SLE) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of This report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, sex-specific prevalent cases, Lupus Nephritis prevalent cases, diagnosed cases and treatable cases) scenario of Systemic Lupus Erythematosus (SLE) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, the total number of prevalent and diagnosed population of Systemic Lupus Erythematosus (SLE) was found to be more than 5, 76,232 and 850,000 in 7MM respectively, in the year 2016.
Systemic Lupus Erythematosus Drug Chapters
This segment of the Systemic Lupus Erythematosus report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
More than five decades ago, an antimalarial drug, Plaquenil (Hydrochloroquine; Sanofi-Aventis) was approved by USFDA in 1955 for the treatment of SLE. Since then, no drug received approval for SLE treatment until 2011, when GlaxoSmithKline came up with first ever targeted therapy for the treatment of SLE, Benlysta (Belimumab). Detailed chapter for Benlysta, along with the upcoming therapies i.e., Anifrolumab (AstraZeneca), Lupuzor (ImmuPharma), Atacicept (Merck KgaA), IFNa KINOID (Neovacs), Vobarilizumab (Ablynx-Abbvie), CC-220 (Celgene) and Ustekinumab (Janssen Research & Development) have been covered in the report.
Systemic Lupus Erythematosus Market Outlook
The Systemic Lupus Erythematosus market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Systemic Lupus Erythematosus in 7MM was found to be more than USD 720 million in 2016, and is expected to increase at a CAGR of XX% from 2016-2027.
Systemic Lupus Erythematosus Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Systemic Lupus Erythematosus Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Systemic Lupus Erythematosus Report Key Strengths
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
Systemic Lupus Erythematosus Report Assessment
- Current Treatment Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Systemic Lupus Erythematosus market
- Organize sales and marketing efforts by identifying the best opportunities for Systemic Lupus Erythematosus market
- To understand the future market competition in the Systemic Lupus Erythematosus market.